Pesquisar
Abivax SA
ABVXAdicionar à lista de desejos
144.650USD
+12.090+9.12%
Fechamento 07/02, 13:00（ET）Cotações atrasadas em 15 min
0.00Valor de mercado
--P/L TTM
Mais detalhes de Abivax SA Empresa
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Informações de Abivax SA
Código da empresaABVX
Nome da EmpresaAbivax SA
Data de listagemJun 26, 2015
CEOde Garidel (Marc)
Número de funcionários- -
Tipo de títulosDepository Receipt
Fim do ano fiscal- -
Endereço7-11 Boulevard Haussmann
CidadePARIS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísFrance
Código postal75009
Telefone33153830963
Sitehttps://www.abivax.com/
Código da empresaABVX
Data de listagemJun 26, 2015
CEOde Garidel (Marc)
Executivos da empresa Abivax SA
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Pierre Courteille
Mr. Pierre Courteille
Chief Business Officer
Chief Business Officer
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Didier Bruno Blondel
Mr. Didier Bruno Blondel
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
--
--
Ms. Corinna Zur Bonsen-Thomas
Ms. Corinna Zur Bonsen-Thomas
Independent Director
Independent Director
--
--
Mr. Kinam Hong
Mr. Kinam Hong
Director, Representative of Sofinnova Partners
Director, Representative of Sofinnova Partners
--
--
Mr. Jerome Denis, Ph.D.
Mr. Jerome Denis, Ph.D.
Executive Vice President - Process Development & Manufacturing
Executive Vice President - Process Development & Manufacturing
--
--
Mr. Marc de Garidel
Mr. Marc de Garidel
Chief Executive Officer
Chief Executive Officer
--
--
Ms. Ida Hatoum
Ms. Ida Hatoum
Chief People Officer, Chief Compliance Officer
Chief People Officer, Chief Compliance Officer
--
--
Dr. June H. Lee, M.D.
Dr. June H. Lee, M.D.
Independent Director
Independent Director
--
--
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Pierre Courteille
Mr. Pierre Courteille
Chief Business Officer
Chief Business Officer
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Didier Bruno Blondel
Mr. Didier Bruno Blondel
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
--
--
Ms. Corinna Zur Bonsen-Thomas
Ms. Corinna Zur Bonsen-Thomas
Independent Director
Independent Director
--
--
Mr. Kinam Hong
Mr. Kinam Hong
Director, Representative of Sofinnova Partners
Director, Representative of Sofinnova Partners
--
--
Mr. Jerome Denis, Ph.D.
Mr. Jerome Denis, Ph.D.
Executive Vice President - Process Development & Manufacturing
Executive Vice President - Process Development & Manufacturing
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Abivax SA?
Os cinco principais acionistas de Abivax SA são: Mr. Pierre Courteille
Quantas instituições possuem ações da Abivax SA (ABVX)?
Em 2026Q1, 353 instituições possuíam ações da Abivax SA, com valor de mercado aproximado de 61.40M, representando 78.18% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -289711.00.